Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Industry News Roundup: Earnings, User Fee Webinar, UK Ad Enforce

Executive Summary

Sensodyne shines for Glaxo-Novartis JV; and international growth leads Prestige Brands OTCs.

You may also be interested in...



Consumer Industry Roundup: Catalent Acquires Accucaps; CHPA Adds Lobbyist; Zeasorb Recall

Mylan's Schloss joins CHPA government affairs; Catalent expands softgel capabilities with Accucaps acquisition; GKSk recalls a half million bottles of mislabeled Zeasorb; and more news in brief.

Consumer Industry Roundup: Catalent Acquires Accucaps; CHPA Adds Lobbyist; Zeasorb Recall

Mylan's Schloss joins CHPA government affairs; Catalent expands softgel capabilities with Accucaps acquisition; GKSk recalls a half million bottles of mislabeled Zeasorb; and more news in brief.

Taking GSK's Consumer Helm Gives McNamara View From Atop The OTC Space

Brian McNamara becomes GSK Consumer CEO after Emma Walmsley is named to succeed Andrew Witty in 2017 to run Glaxo.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS118905

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel